Tempest Therapeutics (TPST) Corporate presentation summary

Strategic vision and platform overview

• Focus on developing next-generation in vivo CAR-T therapies using a CD7-targeted LNP/mRNA platform for broad T-cell delivery and modular payloads.

• Lead asset TPST-4003 is a dual-target (CD19/BCMA) in vivo CAR-T designed for B-cell lineage reset in autoimmune and oncology indications.

• Platform enables repeat dosing, avoids ex vivo manufacturing and lymphodepletion, and supports scalable, cost-effective production.

• Additional candidates TPST-001 and TPST-002 expand the platform to non-B-cell hematologic malignancies and solid tumors.

Clinical and preclinical progress

• TPST-2003, a dual CAR-T for rrMM and POEMS, showed 100% CR in CAR-T naïve patients and strong safety in early trials.

• TPST-4003 is advancing to IIT validation in MG and MS, with plans for expansion into oncology and rare diseases.

• Platform leverages clinical validation from TPST-2003 to support in vivo strategy.

Market opportunity and competitive landscape

• Large addressable markets in autoimmune diseases (MG, MS, SLE) and oncology (LBCL, B-ALL, rrMM, POEMS) with significant unmet needs.

• TPST-4003 differentiates with pan-T cell delivery, dual-targeting, and repeat dosing, unlike single-target or ex vivo competitors.

• Recent M&A activity in the sector highlights strong pharma interest and high valuations for scalable in vivo CAR-T platforms.